Delcath Systems, Inc. (NASDAQ:DCTH) Financial Performance and Competitive Landscape

Company Overview - Delcath Systems, Inc. is a medical technology company focused on oncology, specifically developing therapies for primary and metastatic liver cancers [1] - The main product is the Hepatic Delivery System, which administers high-dose chemotherapy to the liver while minimizing systemic exposure [1] - Delcath operates in a competitive landscape with peers including Interpace Biosciences, EOM Pharmaceuticals Holdings, Aeterna Zentaris, and Rennova Health [1] Financial Performance - Delcath's Return on Invested Capital (ROIC) is 3.58%, which is lower than its Weighted Average Cost of Capital (WACC) of 7.61%, indicating insufficient returns to cover capital costs [2] - In comparison, Interpace Biosciences has a positive ROIC of 84.16% with a WACC of 9.41%, resulting in a favorable ROIC to WACC ratio of 8.94, suggesting better capital efficiency than Delcath [3] - EOM Pharmaceuticals Holdings exhibits an impressive ROIC of 1,140.12% and a WACC of 16.82%, leading to a ROIC to WACC ratio of 67.77, indicating strong capital efficiency and growth potential [4] - Aeterna Zentaris and Rennova Health both report negative ROICs, highlighting challenges in generating sufficient returns on invested capital [4]